A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

Inclusion Criteria:

• 1. Signed the informed consent form;
• 2. Male or female subjects with 50~80 years of age;
• 3. Active sub-foveal or juxta-foveal choroidal neovascularization(CNV) lesionssecondary to neovascular age-related macular degeneration(nAMD);
• 4. Total lesion area ≤ 12 disc area(DA);
• 5. BCVA letter score measured at screening of 19~78 letters.

Exclusion Criteria:

• 1. History of uveitis in either eye；
• 2. Current active inflammation or infection in the study eye;
• 3. Central foveal scar, fibrosis or atrophy of macular in the study eye;
• 4. Subretinal hemorrhage area in the study eye ≥ 50% of total lesion size;
• 5. Scar or fibrosis area in study eyes ≥ 50% of total lesion size;
• 6. History or any concurrent ocular condition which, in opinion of investigator,could either confound interpretation of efficacy and safety of ASKG712 or requiremedical or surgical intervention.
• 7. Presence of retinal pigment epithelial tear;
• 8. Previous intraocular operations in the study eye;
• 9. Uncontrolled previous or current glaucoma in either eye, or previous glaucomafiltering operation in the study eye;
• 10. Previous anti-VEGF drug treatment within 60 days prior to screening；
• 11. Diseases that affect intravenous injection and venous blood sampling;
• 12. Systemic autoimmune diseases;
• 13. Any uncontrolled clinical disorders;
• 14. History of allergy or current allergic response to ASKG712 or fluorescein;
• 15. Pregnant or nursing women;
• 16. Subjects should be excluded in the opinion of investigators.